Navigation Links
HPV Data May Aid Vaccine's Effectiveness
Date:3/24/2009

Most cervical cancers arose from strains covered by the shot, study finds

TUESDAY, March 24 (HealthDay News) -- The majority of invasive cervical cancers in New Mexico in the 1980s and 1990s contained DNA from human papillomavirus type 16 (HPV16) and HPV type 18 (HPV18), says a new study.

It also found that women diagnosed with HPV16- or HPV18-positive cancers were an average of five years younger than those diagnosed with cancers associated with other HPV types.

The HPV vaccine (Gardasil) protects against infections caused by HPV16 and HPV18, so the new findings may have implications for future cancer screening programs, the researchers said.

The researchers analyzed U.S. data in the Surveillance, Epidemiology and End Results registry and identified 1,213 cases of in situ cervical cancer diagnosed between 1980 and 1999, as well as 808 cases of invasive cervical cancer diagnosed between 1980 and 1999 in New Mexico.

HPV16 DNA was found in 53.2 percent of invasive cervical cancers, HPV18 DNA was found in 13.1 percent, and HPV45 DNA in 6.1 percent. HPV16 DNA was found in 56.3 percent of in situ cervical cancers, HPV31 DNA in 12.6 percent, and HPV33 DNA in 8 percent.

Patients' median age at diagnosis of invasive cancer with HPV16 and HPV18 was 48.1 years, and 45.9 years, respectively. Median age at diagnosis of invasive cancer with other HPV genotypes was 52.3 years.

The study is in the March 24 online issue of the Journal of the National Cancer Institute.

"To our knowledge, this is the largest study of its kind conducted in a U.S. population," wrote a team led by Cosette M. Wheeler, of the University of New Mexico Health Sciences Center in Albuquerque.

"This study of HPV genotypes in New Mexico provides important baseline data for evaluating the effectiveness of nearly implemented HPV-based technologies, HPV vaccines, and HPV screening in the prevention of cervical cancer," she said. "Moreover, these data can guide the future application of these technologies to maximize the cost-effective, public health benefits of these interventions."

More information

The U.S. Food and Drug Administration has more about HPV.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, March 24, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
2. Better by design: Engineering flu vaccines
3. Information Parents Need on Vaccines and Their Childs Health
4. NBA and WNBA Help Teens Take Their Best Shot at Health With New Vaccines for Teens Educational Campaign
5. Federal Court Declares Vaccines Do Not Cause Autism
6. New test may help to ensure that dengue vaccines do no harm
7. Novel Vaccines Improve Potential for European Vaccines Manufacturers
8. Barrs BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA
9. 109 Medicines and Vaccines Now in Development for HIV/AIDS
10. Researchers discover strategy for predicting the immunity of vaccines
11. Medical societies: Adults need vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HPV Data May Aid Vaccine's Effectiveness 
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: